4.8 Article

Thyroid hormone receptor mutants implicated in human hepatocellular carcinoma display an altered target gene repertoire

Journal

ONCOGENE
Volume 28, Issue 47, Pages 4162-4174

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.265

Keywords

hepatocellular carcinoma; thyroid hormone receptors; gene expression; mutant; dominant negative

Funding

  1. Public Health Service/National Cancer Institute [R37-CA53394]
  2. UC Davis Cancer Center Gene Expression Resource [NCI P30-CA93373]
  3. National Institute of General Medical Sciences [T32-GM007377]

Ask authors/readers for more resources

Thyroid hormone receptors (TRs) are hormone-regulated transcription factors that control multiple aspects of normal physiology and development. Mutations in TRs have been identified at high frequency in certain cancers, including human hepatocellular carcinomas (HCCs). The majority of HCC-TR mutants bear lesions within their DNA recognition domains, and we have hypothesized that these lesions change the mutant receptors' target gene repertoire in a way crucial to their function as oncoproteins. Using stable cell transformants and expression array analysis, we determined that mutant TRs isolated from two different HCCs do, as hypothesized, display a target gene repertoire distinct from that of their normal TR progenitors. Only a subset of genes regulated by wild-type TRs was regulated by the corresponding HCC-TR mutants. More surprisingly, the HCC-TR mutants also gained the ability to regulate additional target genes not recognized by the wild-type receptors, and were not simply restricted to repression, but could also activate a subset of their target genes. We conclude that the TR mutants isolated from HCC have sustained multiple alterations from their normal progenitors that include not only changes in their transcriptional outputs, but also changes in the genes they target; both are likely to contribute to neoplasia. Oncogene (2009) 28, 4162-4174; doi: 10.1038/onc.2009.265; published online 14 September 2009

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Meeting Abstract Oncology

Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with advanced solid tumors

Jeffrey R. Infante, Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Deborah J. Wong, Gerald S. Falchook, Manish Patel, Shubham Pant, Melinda Whiteside, John B. Mumm, Ivan H. Chan, Johanna C. Bendell, Todd M. Bauer, Filip Janku, Milind Javle, Rivka R. Colen, Nizar M. Tannir, Martin Oft

CANCER RESEARCH (2016)

Article Oncology

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors

Aung Naing, Kyriakos P. Papadopoulos, Karen A. Autio, Patrick A. Ott, Manish R. Patel, Deborah J. Wong, Gerald S. Falchook, Shubham Pant, Melinda Whiteside, Drew R. Rasco, John B. Mumm, Ivan H. Chan, Johanna C. Bendell, Todd M. Bauer, Rivka R. Colen, David S. Hong, Peter Van Vlasselaer, Nizar M. Tannir, Martin Oft, Jeffrey R. Infante

JOURNAL OF CLINICAL ONCOLOGY (2016)

Meeting Abstract Oncology

Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1

Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Deborah J. Wong, Karen A. Autio, Gerald S. Falchook, Manish Patel, Shubham Pant, Amita Patnaik, Melinda Whiteside, Johanna C. Bendell, John Mumm, Ivan H. Chan, Gail L. Brown, Peter VanVlasselaer, J. R. Hecht, David S. Hong, Nizar M. Tannir, Martin Oft

CANCER IMMUNOLOGY RESEARCH (2016)

Article Oncology

PEG-rIL-10 treatment decreases FoxP3+ Tregs despite upregulation of intratumoral IDO

Ivan H. Chan, Victoria Wu, Melissa Bilardello, Brett Jorgenson, Harminder Bal, Scott McCauley, Peter Van Vlasselaer, John B. Mumm

ONCOIMMUNOLOGY (2016)

Meeting Abstract Oncology

In vitro functional activity of OMP-336B11, a GITRL-Fc fusion protein, on primary human immune cells

Ivan H. Chan, Ming-Hong Xie, Andrew Lam, Fumiko T. Axelrod, Jennifer Elechko, Angie I. Park, Austin Gurney

CANCER RESEARCH (2018)

Article Multidisciplinary Sciences

PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia

Ivan H. Chan, Dennis Van Hoof, Marina Abramova, Melissa Bilardello, Elliot Mar, Brett Jorgensen, Scott McCauley, Harminder Bal, Martin Oft, Peter Van Vlasselaer, John B. Mumm

PLOS ONE (2016)

Article Oncology

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet P. Ratti, Bianca Rojo, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patrick A. Ott, Gerald S. Falchook, Shubham Pant, Annie Hung, Kara L. Pekarek, Victoria Wu, Matthew Adamow, Scott McCauley, John B. Mumm, Phillip Wong, Peter Van Vlasselaer, Joseph Leveque, Nizar M. Tannir, Martin Oft

CANCER CELL (2018)

Meeting Abstract Oncology

CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-ss for cancer immunotherapy

Chao Guo, Yanying Fan, Alexander Aronov, Qi Zhang, Sombeet Sahu, Mary-Lee Dequeant, Changan Guo, Sushant Karnik, Glenn D. Leary, Chandirasegaran Massilamany, Ivan H. Chan, James B. Trager

CANCER RESEARCH (2022)

Meeting Abstract Oncology

CBLB, CISH and CD70 multiplexed gene knockout with CRISPR/Cas9 enhances cytotoxicity of CD70-CAR NK cells and provides greater resistance to TGF-beta for cancer immunotherapy.

Chao Guo, Yanying Fan, Alexander Aronov, Qi Zhang, Sombeet Sahu, Mary-Lee Dequeant, Changan Guo, Sushant Karnik, Glenn D. Leary, Chandirasegaran Massilamany, Ivan H. Chan, James B. Trager

CANCER RESEARCH (2022)

Meeting Abstract Oncology

CRISPR-Cas9-gRNA RNP mediated gene knockout of TGFBR2 and CISH enhances CD19-CAR NK cell function and provides resistance to TGFβ

Chao Guo, Ivan H. Chan, Luxuan Buren, Yanying Fan, Alexander Aronov, James B. Trager

CANCER RESEARCH (2020)

Meeting Abstract Oncology

Coexpression of a CD19-OX40-CD3ξ CAR with membrane-bound IL-15 enhances natural killer cell function.

Luxuan G. Buren, Chao Guo, Yanying Fan, Alexander Aronov, Xiumin Wu, Daofeng Liu, Ming-Hong Xie, Sasha Lazetic, Ivan H. Chan, James B. Trager

CANCER IMMUNOLOGY RESEARCH (2020)

Meeting Abstract Oncology

PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+T-cell invigoration and polyclonal T-cell expansion in cancer patients

Martin Oft, Aung Naing, Jeffrey R. Infante, Kyriakos P. Papadopoulos, Ivan H. Chan, Cong Shen, Navneet P. Ratti, Karen A. Autio, Deborah J. Wong, Manish R. Patel, Patrick A. Ott, Gerald S. Falchook, Shubham Pant, Annie Hung, John B. Mumm, Matthew Adamow, Scott McCauley, Rakesh Verma, Phillip Wong, Peter VanVlasselaer, Joseph Leveque, Nizar M. Tannir

CANCER IMMUNOLOGY RESEARCH (2019)

Meeting Abstract Oncology

Clinical activity and safety of pegylated human IL-10 (AM0010) in combination with anti-PD1

Aung Naing, Kyriakos P. Papadopoulos, Jeffrey R. Infante, Deborah Jean Lee Wong, Karen A. Autio, Patrick Alexander Ott, Gerald Steven Falchook, Manish R. Patel, Shubham Pant, Amita Patnaik, John B. Mumm, Melinda Whiteside, Ivan H. Chan, Johanna C. Bendell, Todd Michael Bauer, Filip Janku, Rivka R. Colen, Nizar M. Tannir, Peter Van Vlasselaer, Martin Oft

JOURNAL OF CLINICAL ONCOLOGY (2016)

Meeting Abstract Oncology

Anti-tumor activity of PEGylated human IL-10 (AM0010) in patients with pancreatic or colorectal cancer

Kyriakos P. Papadopoulos, Aung Naing, Jeffrey R. Infante, Karen A. Autio, Patrick Alexander Ott, Deborah Jean Lee Wong, Gerald Steven Falchook, Manish R. Patel, Shubham Pant, Melinda Whiteside, John B. Mumm, Ivan H. Chan, Johanna C. Bendell, Drew W. Rasco, Kent C. Shih, Milind M. Javle, Todd Michael Bauer, Rivka R. Colen, Peter Van Vlasselaer, Martin Oft

JOURNAL OF CLINICAL ONCOLOGY (2016)

No Data Available